Mill Creek Capital Advisors LLC Sells 7,631 Shares of Johnson & Johnson (NYSE:JNJ)

Mill Creek Capital Advisors LLC reduced its stake in Johnson & Johnson (NYSE:JNJ) by 3.0% in the 3rd quarter, according to the company in its most recent filing with the SEC. The fund owned 247,517 shares of the company’s stock after selling 7,631 shares during the quarter. Johnson & Johnson makes up 1.0% of Mill Creek Capital Advisors LLC’s investment portfolio, making the stock its 18th largest holding. Mill Creek Capital Advisors LLC’s holdings in Johnson & Johnson were worth $40,113,000 as of its most recent filing with the SEC.

A number of other large investors have also recently added to or reduced their stakes in the stock. Meridian Financial Partners LLC bought a new position in Johnson & Johnson in the 2nd quarter worth $1,626,000. Lmcg Investments LLC lifted its position in shares of Johnson & Johnson by 32.7% during the 3rd quarter. Lmcg Investments LLC now owns 87,162 shares of the company’s stock worth $14,125,000 after purchasing an additional 21,471 shares during the last quarter. WealthPlan Investment Management LLC boosted its stake in Johnson & Johnson by 7.3% during the 3rd quarter. WealthPlan Investment Management LLC now owns 61,691 shares of the company’s stock valued at $9,998,000 after purchasing an additional 4,174 shares during the period. Cooper Haims Advisors LLC grew its holdings in Johnson & Johnson by 6.4% in the 1st quarter. Cooper Haims Advisors LLC now owns 3,358 shares of the company’s stock valued at $531,000 after buying an additional 201 shares during the last quarter. Finally, Trajan Wealth LLC increased its position in Johnson & Johnson by 11.3% in the 3rd quarter. Trajan Wealth LLC now owns 32,992 shares of the company’s stock worth $5,347,000 after buying an additional 3,341 shares during the period. Institutional investors own 69.55% of the company’s stock.

Johnson & Johnson Stock Performance

Shares of NYSE:JNJ opened at $154.00 on Friday. The company has a debt-to-equity ratio of 0.45, a current ratio of 1.03 and a quick ratio of 0.79. The business’s fifty day moving average price is $161.35 and its two-hundred day moving average price is $156.10. Johnson & Johnson has a fifty-two week low of $143.13 and a fifty-two week high of $168.85. The stock has a market capitalization of $370.77 billion, a price-to-earnings ratio of 22.29, a price-to-earnings-growth ratio of 2.74 and a beta of 0.53.

Johnson & Johnson (NYSE:JNJ) last posted its earnings results on Tuesday, October 15th. The company reported $2.42 earnings per share for the quarter, topping the consensus estimate of $2.21 by $0.21. Johnson & Johnson had a net margin of 19.14% and a return on equity of 35.45%. The business had revenue of $22.47 billion for the quarter, compared to analyst estimates of $22.17 billion. During the same quarter in the prior year, the firm earned $2.66 EPS. The firm’s quarterly revenue was up 5.2% compared to the same quarter last year. As a group, analysts predict that Johnson & Johnson will post 9.93 EPS for the current fiscal year.

Johnson & Johnson Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, December 10th. Stockholders of record on Tuesday, November 26th will be issued a $1.24 dividend. This represents a $4.96 annualized dividend and a dividend yield of 3.22%. The ex-dividend date is Tuesday, November 26th. Johnson & Johnson’s payout ratio is currently 71.78%.

Insider Buying and Selling

In other Johnson & Johnson news, VP Robert J. Decker sold 5,635 shares of the business’s stock in a transaction on Friday, August 30th. The stock was sold at an average price of $165.06, for a total value of $930,113.10. Following the transaction, the vice president now owns 18,973 shares of the company’s stock, valued at approximately $3,131,683.38. The trade was a 22.90 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. 0.16% of the stock is owned by corporate insiders.

Analyst Ratings Changes

Several brokerages have recently issued reports on JNJ. StockNews.com upgraded shares of Johnson & Johnson from a “buy” rating to a “strong-buy” rating in a research note on Saturday, September 14th. Citigroup raised their price target on shares of Johnson & Johnson from $180.00 to $185.00 and gave the stock a “buy” rating in a research report on Wednesday, October 16th. Royal Bank of Canada upped their price objective on shares of Johnson & Johnson from $178.00 to $181.00 and gave the company an “outperform” rating in a research report on Wednesday, October 16th. Daiwa Capital Markets downgraded Johnson & Johnson from an “outperform” rating to a “neutral” rating and decreased their target price for the stock from $160.00 to $150.00 in a research report on Tuesday, July 23rd. Finally, Wolfe Research began coverage on Johnson & Johnson in a research report on Friday. They issued an “outperform” rating and a $190.00 price objective for the company. Seven equities research analysts have rated the stock with a hold rating, eight have assigned a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat.com, Johnson & Johnson has an average rating of “Moderate Buy” and a consensus price target of $175.94.

About Johnson & Johnson

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.